## Index

A–a gradient, 128  
abdominal computed tomography scan, 79  
abdominal haemorrhage, 203  
acid–base balance, 114–115, 118–121, 207  
acidos, 202  
cinar cells, 73  
activated clotting time, 205  
activated partial thromboplastin time (APTT), 205  
activated protein C, 99  
acute care nurse practitioner (ACNP), 2–3  
acute coronary syndrome (ACS), 28, 31, 35–39  
acute dialysis quality initiative (ADQI), 53  
acute interstitial nephritis (AIN), 45  
acute kidney injury, 53  
acute lung injury (ALI), 105, 107  
acute myocardial infarction, 33  
acute pancreatitis, 75–77, 81–82, 84  
Acute Physiology and Chronic Health Evaluation II (APACHE II) scale, 79  
acute renal dysfunction (ARD), 53  
acute renal failure (ARF), 26  
acute respiratory failure, patient with, 105–140  
alterations in surfactant, 109  
altered pulmonary vascular tone, 109  
artrial blood gas analysis, 114–121  
assessment, 109–114  
diagnosis, 109–114  
evidence-based care, 122–127, 136–140  
inflammatory response, 107–108  
on-going assessment, 128–136  
on-going patient scenario, 127  
pathophysiology, 106–109  
patient scenario, 105–106  
physiology, 106–109  
progressing pathophysiology, 127–128  
acute tubular dysfunction, 45  
acute tubular injury, 45  
acute tubular necrosis (ATN), 45  
adaptive support ventilation, 155  
adenosine diphosphate, 19  
adenosine triphosphate (ATP), 10, 29, 174  
administration of drotrecogin alpha in early sepsis (ADDRESS), 99  
adrenaline, 85  
adrenocorticotropic hormone (ACTH), 217  
adsorption, 60  
advanced critical care practitioners, 6  
adventitious sounds, 111  
aerobic respiration, 10–11  
afterload, 31  
aviary, 32, 77, 101, 145, 167, 194, 222  
alergies, 78  
alpha cells, 74  
alteplase, 37  
alveolar macrophages, 108  
American College of Chest Physicians (ACCP), 14  
ammonia buffer, 121  
anerobic metabolism, 29  
anerobic respiration, 10, 12  
angina, 28  
angiotensin II, 43  
angiotensinogen, 85  
anion gap, 222–223  
anterior–posterior (AP) compression fractures, 198  
anti-biotics, 82  
anticoagulation, 28, 64–65  
antiduretic hormone (ADH), 85, 176–177, 193  
anti-secretory agent, 83  
antithrombin, 22  
aortic aneurysms, 50
aortic valve regurgitation, 50
apoptosis, 46, 108
aprotinin, 210
aspirin, 36
assistant critical care practitioner, 6
atherosclerosis, 28
auscultation, 111
Australian ICU liaison nurse model, 4
autocoid control, 43
autodigestion, 75
autonomy, 2
A waves, 179

barbiturates, 183
beneficence, 251–252
Benzodiazepines, 171, 183
bicarbonate buffer system, 116
bicarbonate ions, 119–120, 224–225
bicarbonate replacement, 224
bispectral index, 180
blast injury, 189
blood cells, 16
blood flow, 166
blood gas analysis, 106, 114–121, 162
blood pressure control, 211–212
blood pressure monitoring, 47
blood product transfusion, 208–210
blood purification, 61
Blood transfusion, 207–208
blood urea nitrogen (BUN), 51, 53
blunt trauma, 189
Brain Trauma Foundation (BTF), 169
breathing, 32, 77, 101, 145–147, 167, 222
British Medical Association (BMA), 251
bronchoalveolar lavage (BAL), 108
B waves, 179

calcium chloride, 65
capillary filtration coefficient, 44
capillary membrane, 44
carbon dioxide, 169
carboxypeptidase enzyme, 73
cardiac depression, 201
cardiac output measurement, 30, 48–49
cardiogenic shock, 41–42
cardiovascular function, 54–56
cardiovascular homeostasis, 40
catecholamines, 219
C-clamp, 211
Cellular respiration, 10–12
cellulose-based membranes, 60
central diabetes insipidus, 177
central venous pressure (CVP), 47, 82, 171, 223
cerebral blood flow (CBF), 162, 164–165, 175–180
cerebral compliance, 166
cerebral function activity monitors (CFAM), 180
cerebral function monitoring, 179–180
cerebral ischaemia, 175
cerebral microdialysis, 180
cerebral perfusion pressure, 164–165, 171
cerebrospinal fluid (CSF), 166
cervical spine control, 191
chemical acid–base buffer system, 115
chemokines, 17
chemotaxis, 16
chest pain, PQRST pain assessment for, 33
chest X-ray, 113–114
cholecystokin hormone, 73
chronic obstructive pulmonary disease (COPD), 48, 143–144, 150–151
chronic pancreatitis, 74
chronic respiratory failure, patient with, 143–158
chymotrypsinogen, 73
circulation, 112
citrate toxicity, 207
citric acid (Kreb’s) cycle, 11–12
clinical nurse specialist (CNS), 3
Clopidogrel, 36
clotting cascade, 21
cogulation cascade, 20, 23, 89–90
cogulopathy, 23, 189
cognitive function, 232
cold thermodilution, 48–49
collateral blood supply, 164
common bile duct (CBD), 73
computed tomographic (CT) scan, 162
confusion assessment method (CAM), 232
constant flow, 130–131
consultant nurse, 4
contact activation pathway, 22
contemporary critical care, challenges in, 1–7
continuous positive airway pressure (CPAP), 154
continuous renal replacement therapy (CRRT), 40, 58, 63–64
continuous veno-venous haemodiafiltration (CVVHDF), 57, 63
continuous veno-venous haemodialysis (CVVHD), 57, 61
continuous veno-venous haemofiltration (CVVH), 62–63
contractility, 31
correlation, 59
Cor pulmonalae, 147, 149
Cori cycle, 12
coronary artery, occlusion of, 29
coronary circulation perfuses, 30
coronary thrombosis, 28
corticosteroid therapy, 98
corticotrophin stimulation tests, 98
craniecomy, decompressive, 185
C-reactive protein (CRP), 18
creatine kinase (CK), 35  
critical care nurse, career progression for, 5  
critical care outreach team, 4  
critical illness polyneuropathy (CIP), 234, 237–238  
critical illness, physiological basis of, 9–25  
cryoprecipitate, 209  
Cullen’s sign, 77  
curative role, 258  
C waves, 179  

cyanosis, 155  
3,5 Cyclic adenosine monophosphate (cAMP), 176  
cyclic adenosine monophosphate (cAMP), 55  
cyclo-oxygenase-2 (COX-2), 109  
cytokines, 23  
D-dimer assay, 205  
declerating flow, 131  
decleration, 189  
decision-making skills, 2  
de compressive craniectomy, 185  
deflation, 55  
degloving injury, 196, 211  
delirium, 232–233  
Delta cells, 74  
deonatology, 249  
dexamethasone, 98  
diabetes insipidus, 176–177  
diabetic emergency, patient with, 215–226  
diabetic ketoacidosis (DKA), 216–221  
diapedesis, 16, 89  
diaphoresis, 155  
disseminated intravascular coagulation (DIC), 23–24  
dobutamine, 55, 97  
dopamine, 57, 96  
dramatic ethics, 248  
drug, use of, 99  
duct of Worsung, 73  

early warning score (EWS), 91  
elastance, 166  
electrocardiograms (ECGs), 34, 78  
electroencephalography, 179  
electromyography (EMG), muscle strength functions, 237  
empowerment, staff, 1  
end-diastolic volume (EDV), 30  
endocardium, 29  
end-organ hypoperfusion, 23  
enoscopic retrograde cholangiopancreatography (ERCP), 75  
endothelial cells, 19–20, 28  
endothelial injury, 18  
endothelium, 44  
endothelium-derived relaxing factor (EDRF), 28  
enzyme transmission, 189  
enrolled nurse, 5  
epicardium, 29  
ethical considerations, 247–258  
etics, 248  
euthanasia, 254–256  
everyday ethics, 248  
expiratory positive airway pressure (EPAP), 152  
exposure, 113–114  
extracorporeal membrane oxygenation (ECMO), 140  
extravascular lung water (EVLW), 48, 49–50  
extravasation, 88  
extrinsic pathway, 21  
Fentanyl, 171, 182  
filtrinogen, 19  
filtrinolysis, 23  
Fick equation, 47  
filtration membrane, 60  
flow time, 50, 130–131  
fluids, 81–82, 93–95, 223–224  
focal hypoxic/ischaemic insults, 174  
fouling, 59  
fraction of inspired oxygen (FIO2), 138  
Frank–Starling law, 30–31  
fresh frozen plasma (FFP), 208, 209  
front-end trauma care, 190  
full blood count, 72  
fundamental residual capacity (FRC), 121  
Garr equation, simplified, 48  
general medical services (GMC), 2  
Glasgow Coma Score (GCS), 148, 162, 168  
global end-diastolic volume (GEDV), 49  
global hypoxic/ischaemic insults, 174  
Global Initiative for Obstructive Lung Disease (GOLD), 143  
glomerular filtration membrane, 44  
glomerular filtration rate (GFR), 42–44, 51–53  
glucagon, 74  
glucoctocortiods, 219–220  
gluconeogenesis, 74  
glucose-dependent insulin tropic peptide (GIP), 217  
glucose transporter 4 (GLUT4), 220  
glyceryl trinitrate (GTN), 27  
glycogenolysis, 73, 74  
glycolysis, overall reaction of, 11  
guanosine monophosphate, 97  
haematocrit, 180–182  
haemodialfiltration, 62–63  
haemodialysis, 61
haemodynamic patient, 26–65
haemodynamics, 170–171
haemofiltration, 62
haemostasis, 19–24, 27
haemostasis, assessment of, 205–206
health-care, significant impact on, 4
health-related quality of life (HRQL), 240, 241
Henderson–Hasselbach equation, 116
heparin, 64
heparinoids, 64
high molecular weight kininogen (HMWK), 22
histamine, 17, 202
host micro-organism, 17
6-Hour bundle, 92
24-Hour bundle, 97
human growth hormone, 217
hydrocortisone, 98
hydrogen ions, 115–121
hydrophilic membranes, 59
hyperaemic phase, 167
hypercapnia, 100
hyperglycaemia, 218
hyperketaoniaemia, 218
hypertonie solution, 185
hyperventilation, 169
hypoglycaemia, 100
hypokalaemia, 207
hypoperfusion phase, 167
hypotension, 85, 170
hypothermia, 208, 212
hypovolaemia, 75, 85
hypovolaemic shock, 84–85
hypoxaemia, secondary brain injury, 170
hypoxanthine, 13
hypoxia, 30
hypoxic pulmonary vasoconstriction, 109
hypoxic states, 13
impact energy, 189
Imrie scoring system, 79
inducible nitric oxide synthase (iNOS), 109
infarctions, 29
inflammation, 16–18, 87–88
inflammatory mediators, 88
inflammatory response, 14–16, 19
inhaled nitric oxide (iNO), 140
innermost arterial layer, 28
inotropes, 95–96
inspiratory positive airway pressure (IPAP), 152
insulin, 74, 217, 224
Intensive Care Society, 64
Intensive Care Unit (ICU), 1, 143
intensive care unit, long-term patient in, 228–245
intermittent haemodialysis (IHD), 58
International Council for Nurses (ICN), 2
intra-aortic balloon pump therapy (IABP), 55–56
intracranial insult, patient with, 161–185
altered level of consciousness and, 163
assessment, 167–168
blood gas analysis, 162
causes of, 163
cerebral blood flow following injury, changes to, 167
cerebral metabolic needs, 163
diagnosis, 167–168
evidence-based care, 168–172, 180–185
intracranial pressure, control of, 166
monitoring of, 179
neuronal protection, 164–166
ongoing assessment, 177–180
ongoing patient scenario, 172–173
pathophysiology, 162–167
patient scenario, 161–162
physiology, 162–167
primary brain injury, 162
progressing pathophysiology, 174–177
raised intracranial pressure, other causes of, 163–164
secondary brain injury, 162
waveforms, 179
intra-renal renal failure, 45
intrathoracic blood volume (ITBV), 49
intravenous hydrocortisone, 98
intravenous opioids, 83
intrinsic pathway, 22
intubation, complications of, 151
invasive procedures, 3
inverse ratio ventilation, 138
irreversible ischaemia, 29
ischaemia, 13–15, 29, 34, 174–175
Islets of Langerhans, 217
jaundice, 208
John’s cyclic psychological/physiological effects, 230
jugular bulb oximetry, 178
jugular venous saturation, 178–179
justice, 252
Kellie–Monroe doctrine, 166
kinins, 18
Kreb’s cycle, 11
lactate dehydrogenase (LDH), 35
Langerhans, 74
lateral compression injury, 198–199
left anterior descending (LAD) artery, 30
leucocyte–endothelial interactions, 46
leucocytes, 88
leukotrienes, 17
lipid-derived chemical mediators, 17
lithium, 50
long-term oxygen therapy (LTOT), 158
loops, 134–136
low volume–fluid resuscitation, 194–195
Lund therapy protocol, 170
lymphocytes (B and/or T), 16

macrophages, 16
macula densa, 43
magnesium, 225
mannitol, 185
mannose-binding protein, 18
margination, 16
massive systemic reaction, 16
mean arterial pressure (MAP), 164–165, 170–171
mechanical ventilation, 137–138, 169–170, 180–181
mechanisms of injury, 189–190
medical assessment unit (MAU), 71
Medical Research Council (MRC) dyspnoea scale, 148
membrane, fouling, 59
memories, 231
metabolic acidosis, 218
methicillin-resistant staphylococcus aureus (MRSA), 93
methylene blue, 97
methylprednisolone, 98
microvascular thrombosis, 18
midazolam, 171, 182
milrinone, 55
mobility, 239–240
modified early warning score (MEWS), 253
morphine, 36, 83
morphine sulphate, 182
motorcycle-related trauma, 190
mucoytic therapy, 158
multidisciplinary team (MDT), 230
multiorgan failure (MOF), 9, 23, 237
multiple organ dysfunction syndrome (MODS), 14, 107, 190
muscle relaxants, 183
myocardial infarction (MI), 26, 29–30
myocardial necrosis, 33
myocardium, 29–30, 40
myogenic autoregulation, 43
myogenic mechanism, 43

National Confidential Enquiry into Patient Outcome and Death (NCEPOD), 233
National Education and Competence Framework for Advanced Critical Care Practitioners, 6
National Health Service (NHS), 4
near-infrared spectrometry, 178

necrosis, 46
necrotic myocardial tissue, 29
negative inotropic agents, 31
nephron, Bowman’s capsule of, 43
neuroendocrine disorders, 176–177
neuromonitoring, 177–178
neuronal protection, 164–166
neutrophils, 16
nitric oxide (NO), 14, 97, 140
noise, 231
non-invasive ventilation (NIV), 143, 150–152
non-invasive ventilatory support, 149
non-responders, 195
non-ST segment elevation myocardial infarction (NSTEMI), 28
nonadrenaline, 85, 96–97, 219
normal flow, 52
normoglycaemia, 184
normovolaemia, 181
nurse practitioner, 3
nutrition, 82, 184, 238–239

open-book fracture, 198
opioids, 182–183
oponisation, 89
organelle zone, 20
osmoreceptors, 85
osmotic diuresis, 219
outreach nurse, 4
oxygenation, 36, 82, 148–149, 170

pain control, 82–83
palpation, 110–111
pancreas, 72, 73
pancreatic amylase, 73
pancreatic ducts, 73
pancreatic pseudocysts, 76
pancreatitis, 74–76
Passy-Muir valve, 236
patient autonomy, 242
peak velocity, 51
pelvic injuries, 197–200
penetrating injury, 189
perception, altered, 231
perfusion, energy production, impact on, 12–13
peripheral arterial waveforms, 49
peritoneal dialysis, 61
permissive hypotension, 194–195
persisting ethics, 248
pethidine, 83
pH, 115
phagocytic cells, 16
pharmacology, 3
phosphate, 225
phosphate buffer system, 117
Index

phosphodiastase, 55
physical assessment techniques, 3
physical disorders, 229
physician assistant, 5–6
platelet disruption, 28
plasma cascade systems, 84
plasma enzyme systems, 18
plasma proteins, 20–22
plasmin, 37
platelet-activating factor (PAF), 108
platelet factor 3, 20
platelet membrane, 19
platelets, 19, 209
platelet transfusion, indications for, 209
positive end expiratory pressure (PEEP), 48, 100, 170
positive-pressure ventilation, 122–123
post-dilution, 62
post-traumatic stress disorder (PTSD), 233–234
potassium, 224
pre-dilution, 62
pre-load, 30–31
pressure control, 106
pressure-cycled ventilation, 130
pressure-regulated volume control (PRVC), 173
pressure support, 106
pressure-support ventilation (PSV), 155
pressure–time diagram, 130
pressure–volume loop, 134–135
primary brain injury, 162
primary haemostasis, 20
primary percutaneous coronary intervention (PPCI), 35, 38–39
principal duct, 73
pro-inflammatory cytokines, 17
prolonged ischaemia, 13
propofol, 171, 182
prostacyclin nebulisers, 139
prostacyclin, 28, 64
prostaglandins, 17
protamine, 210
protein C worldwide evaluation of severe sepsis (PROWESS), 99
proteolytic cascade, 20
prothrombin time, 205
prothrombogenic, 20
P-selectin, 88
pseudomonas, 93
psychological disorders, 229
pulmonary artery catheter (PAC), 47–49
pulmonary artery diastolic pressure, 48
pulmonary artery occlusion pressure, 48
pulmonary capillary hydrostatic pressure (PCP), 48
pulmonary complications, 76
pulmonary emboli, 76
pulse pressure, 193
pupillary response, 168
quality of life, 240–241
Ranson’s criteria, 79
rapid fluid replacement, 223
receptor tyrosine kinase, 220
recombinant activated factor VII, 209
recombinant human activated protein C (rhAPC), 98
refractory hypotension, 13
regional heparinisation, 64
rehabilitation, 241–244
renal effects, 42–46
autacoid control, 43
glomerular filtration, 43–44
hormonal control, 43
inflammatory involvement, 46
intra-renal renal failure, 45
myogenic autoregulation, 43
post-renal renal failure, 46
pre-renal renal failure, 42
renal blood flow, 42–43
renal cell death, 46
sympathetic nervous system, 42
tubular dysfunction, 45
tubuloglomerular feedback, 43
tubuloglomerular feedback mechanisms, 45–46
renal function, 51–54, 56–57
renal replacement therapy (RRT), 56–63
adsorption, 60
aims of, 58
cellulose-based membranes, 60
clearance, concept of, 60
elevated creatinine levels, 57
filtration membrane, 60
fluid overload, 57
haemodiafiltration, 62–63
haemodialysis, 61–62
haemofiltration, 62
hyperkalaemia, 57
methods of, 58
modes of, 61
peritoneal dialysis, 61
principles of, 58–59
sieving coefficient, 60
slow continuous ultrafiltration, 63
synthetic membranes, 60
timing of, 57
uncontrolled/worsening metabolic acidosis, 57
uraemia complications, 57
vascular access, 60–61
renal system, 115
renin–angiotensin–aldosterone system (RAAS), 43, 85
Index 

reperfusion, 13–14, 36–37, 39
respiratory burst, 90
respiratory centre, 115
respiratory gases, 181
respiratory physical assessment, 110–112
resuscitation, 94
reteplase, 37
RIFLE criteria, 54

scoring systems, 79–81
secondary brain injury, 162, 174
secondary haemostatic mechanism, 20–22
sedation, 234–235
selective decontamination of the digestive tract (SDD), 82
self-rule, 250
sepsis, 14, 84–87
sepsis management bundle, 98–100
septic patient, 71–100
assessment, 76–81
diagnosis, 76–81
early identification of, 91–100
evidence-based care, 81–83,
91–100
ongoing patient scenario, 83–84
pancreatic physiology, 72–74
pathophysiology, 74–76
patient scenario, 71–72, 83–84
progressing pathophysiology, 84–91
risk factors, identification of, 77–78
scoring systems, 79–81
serotonin, 202
serum amylase, 78
severe sepsis, 87, 91–97
severe sepsis resuscitation bundle, 91–97
antibiotic administration, blood cultures obtained prior to, 92
broad-spectrum antibiotics, improve time to, 92–93
central venous oxygenation, maintain adequate, 95
dobutamine, 97
dopamine, 96
elevated lactate with fluids, treatment of, 93–95
hypotension treatment with fluids, 93–95
inotropes, 95–96
methylene blue, 97
noradrenaline, 96–97
serum lactate measured, 91–92
vasopressors, 95–96
sexual dysfunction, 238
shock, progressive stage of, 201–203
short-acting drugs, 171
sieving coefficient, 60
slow continuous ultrafiltration (SCUF), 63
social adjustment, 242
Society of critical care medicine (SCCM), 14
sodium, 225
soft tissue injury, 195
sol-gel zone, 20
solute, 59–60
somatostatin, 74
specific ethics, 248
Spinal Cord Injury Information Network, 238
spontaneous breathing trial (SBT), 153–155
spontaneous thrombosis, 28
ST segment elevation myocardial infarction (STEMI), 27, 28, 33, 35, 37
steroids, 98
stored blood, 208
stroke volume, 30, 51
stroke volume variation (SVV), 50
Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment (SUPPORT), 255
sufentanil, 183
sympathetic nervous system, 42
synchronised intermittent mandatory ventilation (SIMV), 106, 155
synthetic membranes, 60
systemic coagulopathy, 18
systemic heparinisation, 64
systemic inflammatory response syndrome (SIRS), 14–15, 85–87, 107, 237
systemic inflammatory syndrome (SIS), 14
systemic vascular resistance, 50–51, 55, 96
tachyphylaxis, 171
technical ethics, 248
tenecteplase, 37
thermal injury, 189
third space fluid loss, 85
thrombin clotting time, 205
thrombocytopenia, 23
thromboelastography®, 205–206
thrombolysis, 37–38
thrombolysis in myocardial infarction (TIMI) flow grading system, 37
thrombolytic therapy, 35, 38
thrombus formation, 27–28
thrombus, 28
thyroxine (T4), 220
tissue factor pathway, 21
tissue perfusion, 54
total parenteral nutrition (TPN), 82
T-piece SBT, 154
tracheostomy, 156, 235–236
tranexamic acid, 210
transcerebral refill, 201
transcranial doppler, 178–179
transforming growth factor alpha (TGF-α), 128
transforming growth factor beta (TGF-β), 128
transfusion related acute lung injury (TRALI), 208
transient responders, 195
transitional care, 242–243
transmembrane pressure gradient (TMP), 59
transmigration, 89
transoesophageal doppler, 50–51
transpulmonary indicator dilution, 49
transpulmonary thermodilution, 49–50
traumatic head injury, 161, 172
traumatic injury, patient with, 188–212
triiodothyronine (T3), 220
trimodal death distribution, 190
trypsin, 73
tubular lumen, 45
tubular system, 20
tubuloglomerular feedback mechanisms, 43, 45–46
 tumour necrosis factor (TNF), 46, 75, 108
type I diabetes, 217–218
type II diabetes, 218
type II respiratory failure, 150
ultrafiltration, 59
ultrasound scans, 79
United States, 3
urinary tract infection (UTI), 218
vasoactive agents, 182
vasodilation, 16
vasomotor failure, 202
vasopressors, 95–96
vasospastic phase, 167
ventilation, modes of, 124–126, 139–140
ventilation perfusion (V/Q) imbalance, 107, 144
vertical shear injury, 198–199
vitamin K, 210
volume control, 161
volume-cycled ventilation, 129–130
Von Willebrand factor, 19
warfarin, 210
warm thermodilution, 49
waveforms, 131–134
weaning, 153–157
wedge pressure, 48
work of breathing, 110